Janssen-Cilag International withdraws application for Velcade (bortezomib)
Janssen-Cilag International NV on September 2, 2011, submitted an application to extend the marketing authorisation for Velcade in combination with rituximab for the treatment of patients with relapsed follicular non-Hodgkin lymphoma. At the time of ...
J&J pulls file to extend Velcade's use in EU
Janssen withdraws attempt to extend Velcade indication in EU
Johnson & Johnson pulls EU submission for Velcade use in NHL